2015•Unpublished venueRequires access

The Value of Pepsinogen Iand Pepsinogen II in the Screening of Gastric Cancer

Che Hu-se

Open publisher page 0 citations

Abstract

Objective To explore the diagnostic value of pepsinogen Ⅰ( PG Ⅰ) and pepsin Ⅱ( PG Ⅱ) in the screening for gastric cancer. Methods 15 patients with gastric cancer,20 patients with atrophic gastritis,23 cases of gastric ulcer patients,25 cases of superficial gastritis patients and 80 healthy physical examination personnel were selected in this study. The PG Ⅰ and PG Ⅱ content were detected by using latex enhanced immune transmission turbidimetry. Results The PG Ⅰ content in gastric cancer patients,patients with atrophic gastritis,gastric ulcer patients,superficial gastritis patients and physical examination personnel were 37. 13 ±18. 59 ng / m L,39. 27 ± 16. 29 ng / m L,180. 42 ± 61. 27 ng / m L,128. 12 ± 14. 65 ng / m L and 120. 19 ± 16. 96 ng /m L respectively. The PG I in patients with gastric cancer and atrophic gastritis group were significantly lower than that of normal controls( P 0. 05). The PG Ⅱ content in gastric cancer patients,patients with atrophic gastritis,gastric ulcer patients,superficial gastritis patients and physical examination personnel were 20. 67 ±9. 59 ng / m L,16. 35 ± 16. 89 ng / m L,22. 95 ± 13. 46 ng / m L,8. 05 ± 4. 04 ng / m L,and 11. 85 ± 9. 65 ng / m L respectively. There was no significant difference between each groups( P 0. 05). The positive rate of PG Ⅰand PG Ⅱ in patients with gastric cancer and atrophic gastritis group were significantly higher than other groups( P 0. 05). Conclusion The detection of PG Ⅰ and PG Ⅱcould provide significant value in the gastric cancer and atrophic gastritis disease screening and diagnosis.

About this research paper

What this paper is about

Objective To explore the diagnostic value of pepsinogen Ⅰ( PG Ⅰ) and pepsin Ⅱ( PG Ⅱ) in the screening for gastric cancer. Methods 15 patients with gastric cancer,20 patients with atrophic gastritis,23 cases of gastric ulcer patients,25 cases of superficial gastritis patients and 80 healthy physical examination personnel were selected in this study. The PG Ⅰ and PG Ⅱ content were detected by using latex enhanced immune transmission turbidimetry. Results The PG Ⅰ content in gastric cancer patients,patients with atrophic gastritis,gastric ulcer patients,superficial gastritis patients and physical examination personnel were 37. 13 ±18. 59 ng / m L,39. 27 ± 16. 29 ng / m L,180. 42 ± 61. 27 ng / m L,128. 12 ± 14. 65 ng / m L and 120. 19 ± 16. 96 ng /m L respectively. The PG I in patients with gastric cancer and atrophic gastritis group were significantly lower than that of normal controls( P 0. 05). The PG Ⅱ content in gastric cancer patients,patients with atrophic gastritis,gastric ulcer patients,superficial gastritis patients and physical examination personnel were 20. 67 ±9. 59 ng / m L,16. 35 ± 16. 89 ng / m L,22. 95 ± 13. 46 ng / m L,8. 05 ± 4. 04 ng / m L,and 11. 85 ± 9. 65 ng / m L respectively. There was no significant difference between each groups( P 0. 05). The positive rate of PG Ⅰand PG Ⅱ in patients with gastric cancer and atrophic gastritis group were significantly higher than other groups( P 0. 05). Conclusion The detection of PG Ⅰ and PG Ⅱcould provide significant value in the gastric cancer and atrophic gastritis disease screening and diagnosis.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To explore the diagnostic value of pepsinogen Ⅰ( PG Ⅰ) and pepsin Ⅱ( PG Ⅱ) in the screening for gastric cancer. Methods 15 patients with gastric cancer,20 patients with atrophic gastritis,23 cases of gastric ulcer patients,25 cases of superficial gastritis patients and 80 healthy physical examination personnel were selected in this study. The PG Ⅰ and PG Ⅱ content were detected by using latex enhanced immune transmission turbidimetry. Results The PG Ⅰ content in gastric cancer patients,patients with atrophic gastritis,gastric ulcer patients,superficial gastritis patients and physical examination personnel were 37. 13 ±18. 59 ng / m L,39. 27 ± 16. 29 ng / m L,180. 42 ± 61. 27 ng / m L,128. 12 ± 14. 65 ng / m L and 120. 19 ± 16. 96 ng /m L respectively. The PG I in patients with gastric cancer and atrophic gastritis group were significantly lower than that of normal controls( P 0. 05). The PG Ⅱ content in gastric cancer patients,patients with atrophic gastritis,gastric ulcer patients,superficial gastritis patients and physical examination personnel were 20. 67 ±9. 59 ng / m L,16. 35 ± 16. 89 ng / m L,22. 95 ± 13. 46 ng / m L,8. 05 ± 4. 04 ng / m L,and 11. 85 ± 9. 65 ng / m L respectively. There was no significant difference between each groups( P 0. 05). The positive rate of PG Ⅰand PG Ⅱ in patients with gastric cancer and atrophic gastritis group were significantly higher than other groups( P 0. 05). Conclusion The detection of PG Ⅰ and PG Ⅱcould provide significant value in the gastric cancer and atrophic gastritis disease screening and diagnosis.

Key concepts: Medicine, Atrophic gastritis, Gastroenterology, Internal medicine, Pepsin, Gastritis, Cancer, Significant difference

Related papers

Back to paper searchBrowse research topicsOriginal source
The Value of Pepsinogen Iand Pepsinogen II in the Screening of Gastric Cancer — Research Paper | ScholarLens